Genetically targeting Nrp1 impedes the entry of TAMs into hypoxic regions, which are retained in the normoxic regions instead, preventing immunosuppression and angiogenesis and promoting anti-tumour immunity. This evidence concerns the gene NRP1 and neoplasm.